Have a feature idea you'd love to see implemented?
Let us know!
BCLI Brainstorm Cell Therapeutics Inc
Price (delayed)
$2.04
Market cap
$11.63M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.51
Enterprise value
$12.31M
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of
Highlights
BCLI's debt has plunged by 71% YoY and by 13% from the previous quarter
The EPS has increased by 46% year-on-year
The net income has increased by 14% YoY but it has decreased by 12% QoQ
The equity has plunged by 135% YoY and by 72% from the previous quarter
BCLI's quick ratio has shrunk by 93% QoQ and by 87% YoY
Key stats
What are the main financial stats of BCLI
Market
Valuations
Earnings
Shares outstanding
5.7M
Market cap
$11.63M
Enterprise value
$12.31M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$14.23M
EBIT
-$13.64M
EBITDA
-$13.38M
Free cash flow
-$11.33M
Per share
Balance sheet
Liquidity
EPS
-$3.51
EPS diluted
-$3.51
Free cash flow per share
-$2.13
Book value per share
-$1.14
Revenue per share
$0
TBVPS
$0.38
Total assets
$2.03M
Total liabilities
$8.08M
Debt
$841,000
Equity
-$6.06M
Working capital
-$6.72M
Debt to equity
-0.14
Current ratio
0.05
Quick ratio
0.03
Net debt/EBITDA
-0.05
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-372.9%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCLI stock price
How has the Brainstorm Cell Therapeutics stock price performed over time
Intraday
0.99%
1 week
-8.52%
1 month
40.69%
1 year
-58.37%
YTD
-10.13%
QTD
-10.13%
Financial performance
How have Brainstorm Cell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.31M
Net income
-$14.23M
Gross margin
N/A
Net margin
N/A
Brainstorm Cell Therapeutics's operating income has increased by 38% YoY and by 18% QoQ
The net income has increased by 14% YoY but it has decreased by 12% QoQ
Growth
What is Brainstorm Cell Therapeutics's growth rate over time
Valuation
What is Brainstorm Cell Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 46% year-on-year
The equity has plunged by 135% YoY and by 72% from the previous quarter
Efficiency
How efficient is Brainstorm Cell Therapeutics business performance
The return on assets has dropped by 56% year-on-year and by 38% since the previous quarter
Dividends
What is BCLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCLI.
Financial health
How did Brainstorm Cell Therapeutics financials performed over time
Brainstorm Cell Therapeutics's total assets is 75% less than its total liabilities
BCLI's quick ratio has shrunk by 93% QoQ and by 87% YoY
Brainstorm Cell Therapeutics's current ratio has shrunk by 90% QoQ and by 79% YoY
BCLI's debt is 114% more than its equity
The equity has plunged by 135% YoY and by 72% from the previous quarter
The company's debt to equity has surged by 88% YoY and by 48% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.